论文部分内容阅读
由上海五洲药厂和上海延安制药厂共同承担的“八五”国家科技攻关项目新型抗高血压药赖诺普利(lisinopril)的研制于4月20日在上海通过验收和鉴定。 ACE抑制剂卡托普利和依那普利国内已生产,赖诺普利最近又为美国药典1995年版收载。本品属国内首先研制成功,与前两种ACE抑制剂比较,具有以下优点:①半衰期和作用时间长,每天服用1次;②与食物吸收互不影响;③不需通过肝脏转化即可产生药理作用,适用于肝功能不良的病人;④不良反应少,耐受性好,安全性高;⑤对充血性心衰的疗效优于卡托普利。本品口服1～2h即起效,5～6h出现最大降压效果,24h后仍有明显作用,血浓峰
The development of lisinopril, a new type of antihypertensive drug, was jointly accepted by Shanghai Wuzhou Pharmaceutical Factory and Shanghai Yan’an Pharmaceutical Factory on April 20 in Shanghai. The ACE inhibitors captopril and enalapril have been produced domestically and lisinopril has recently been accepted for inclusion in the 1995 edition of the U.S. Pharmacopeia. This product is the first successful development of the domestic, with the first two ACE inhibitors compared with the following advantages: ① half-life and the role of a long time, taking 1 day; ② and absorption of each other without affecting each other; ③ without the liver can be transformed into Pharmacological effects, suitable for patients with liver dysfunction; ④ less adverse reactions, good tolerance, high safety; ⑤ curative effect of congestive heart failure better than captopril. This product is oral 1 ~ 2h that is effective, 5 ~ 6h maximum antihypertensive effect, still significant effect after 24h, peak blood concentration